BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Nov 8, 2025 • 9min
Enara Bio publicly announced its first cancer specific 'dark genome antigen' target at SITC - DARKFOX, an alternative open reading frame associated with FOXM1
CEO Kevin Pojasek describes the past challenge of drugging FOXM1, and why he believes DARKFOX will be an ideal target for the company's T-cell engager platform.
Nov 8, 2025 • 12min
Compugen is standing firm on its belief that TIGIT will ultimately succeed with Fc reduced/silent constructs
The company's new CEO Eran Ophir discusses the computational work that when into Compugen's understanding of TIGIT biology, and he walks us through their partnership with AstraZeneca. Plus, recent ESMO data for PVRIG and a trial in progress for IL18BP.
Nov 8, 2025 • 13min
Synthekine presented data at SITC on its α/β-IL-2 receptor biased partial agonist showing a 53% response rate in PD-L1 negative nonsquamous NSCLC
Co-Founder & CEO Debanjan Ray walks us through learnigs the IL-2 space has seen over the years, and describes why Synthekine is targeting both the α and β receptors in this case. In addition to the phase 1a/1b that is reading at SITC, Synthekine has already started a randomized phase 2 study.
Nov 8, 2025 • 9min
Marengo Therapeutics has presented data at ESMO and SITC showing that its lead program, which is designed to activate Vβ6/10 T cells, is active in multiple tumor types
CEO Zhen Su walks us through the data, which had 46 efficacy-evaluable patients and showed a 20% ORR and 80% DCR across multiple tumor types.
Nov 8, 2025 • 8min
Brain shuttle technologies have been in the news a lot lately. Natalie Ricciardi explains what you need to know about 1st and 2nd generation technologies in development.
She and her colleagues at inThought Research recently published a report summarizing the brain shuttle technology research landscape in the biotech sector.
Nov 5, 2025 • 14min
Menlo Ventures published a report showing that the healthcare industry is the leading adopter of AI - one of the co-authors shares the key takeaways
Menlo Ventures Partner, and co-author of the report, Derek Xiao talks about how AI is improving the P&L of health systems and helping with staffing shortages. Medical documentation, billing and scribing are the biggest areas of adoption today, while patient engagement and the post acute relationship are emerging as next to be impacted.
Nov 4, 2025 • 8min
BIO-Europe 2025: Spain based ARTHEx Biotech is a European player in the DM1 space, and believes its microRNA strategy offers a dual benefit that it says is unique to the field
CEO Frédéric Legros walks us through the science and explains why he believes ARTHEx has a unique approach compared to others we have seen in the field. The company raised an $87M series B in September.
Nov 4, 2025 • 8min
BIO-Europe 2025: Sparrow Pharmaceuticals raised a $95M series B last month - it will be testing its cortisol depleting HSD1 inhibitor in type 2 diabetes
CEO Robert Jacks describes the history of learning about how Sparrow's asset lowered cortisol in Cushing's syndrome, and new data suggesting that doing so could be beneficial for treatment-resistant T2D patients.
Nov 4, 2025 • 8min
BIO-Europe 2025: Topas Therapeutics is delivering nanoparticles to the liver to establish tolerance in T-cells for autoimmune and immune-mediated disease - it recently had intriguing data in celiac
CEO Hugo Fry describes the scientific idea behind antigenic tolerization, and discusses Topas' recent PoC data that was presented at Digestive Disease Week.
Nov 4, 2025 • 7min
BIO-Europe 2025: Step Pharma has 'followed the genetics' to be the first company to target CTPS1 inhibition for cancer - CEO Andrew Parker walks us through this unique science
He explains the story of this enzyme and the biology of how CTPS1 and CTPS2 interact. Step is in the clinic in lymphoma and solid tumors, and recently raised a €38 series C.
